DR. BRUCE ALAN PFEFFER, PH.D.
Optometry at Old Post Rd, Fairport, NY

2007004, Mar 1, 2007

Jun 28, 2006

11/476496

Bruce Pfeffer - Fairport NY, US
Rosemarie Flick - Collegeville PA, US
Stephen Bartels - Pittsford NY, US

A61K 31/655, A61K 31/517, A61K 31/498, A61K 31/47

514150000, 514249000, 514266100, 514310000, 514311000, 514248000

Preparations for controlling intraocular pressure in the eye comprise as an active compound, arylazine substituted with a carbonylic moiety, which compound is capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork to promote outflow of aqueous. The organic active compound increases Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for glaucoma, e.g., primary open angle glaucoma.

2012006, Mar 15, 2012

Sep 26, 2011

13/245337

Jinzhong Zhang - Pittsford NY, US
Keith W. Ward - Ontario NY, US
Timothy L. Comstock - Rochester NY, US
Dale W. Usner - Everett WA, US
Bruce A. Pfeffer - Fairport NY, US
Charu A. DeWitt - Pittsford NY, US
Francisco J. Lopez - Victor NY, US
Claudio Bucolo - Catania, IT

A61K 31/4725, A61P 27/02, A61P 29/00, A61K 31/4709

514310, 514314

A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in a method of managing ocular inflammation and/or pain such that it has lower risk of eliciting increased intraocular pressure seen with glucocorticoids.

2010010, Apr 29, 2010

Oct 22, 2009

12/603988

Dharmendra M. Jani - Fairport NY, US
Kai Kwok - Rochester NY, US
Gregory L. McIntire - Rochester NY, US
Bruce A. Pfeffer - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Ruiwen Shi - Cupertino CA, US
Srini Venkatesh - Pittsford NY, US
Hongna Wang - Fairport NY, US
Yan Huang - Webster NY, US
Stephen R. Davio - Fairport NY, US

Talecris Biotherapeutics, Inc. - Research Triangle Park NC

A61K 38/48, A61P 27/02

424 9464

A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

2007013, Jun 14, 2007

Nov 17, 2006

11/601389

Dharmendra Jani - Fairport NY, US
Kai Kwok - Rochester NY, US
Gregory McIntire - Rochester NY, US
Bruce Pfeffer - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Ruiwen Shi - Cupertino CA, US
Srini Venkatesh - Pittsford NY, US
Hongna Wang - Fairport NY, US
Yan Huang - Webster NY, US
Stephen Davio - Fair Port NY, US

A61K 38/48, A61K 31/198

424094640, 514566000

A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

2007013, Jun 14, 2007

Dec 6, 2006

11/567338

Dharmendra Jani - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Bruce Pfeffer - Fairport NY, US
Michael Hartzer - Arlington TX, US

A61K 38/48, C12N 9/64

424094630, 435226000

A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a pH less than about 5, and reconstituting the acidified enzyme substantially immediately before use with a buffer having a pH in the range from about 6.5 to about 11, wherein the pH remains within 1 pH unit upon adding said the enzyme into the buffer. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

2006012, Jun 8, 2006

Jan 20, 2006

11/336536

Bruce Pfeffer - Fairport NY, US
Rosemarie Flick - Copiaque NY, US
Naveed Shams - Duluth GA, US
Stephen Bartels - Pittsford NY, US

A61K 31/47, A61K 31/445, A61K 31/426, A61K 31/405, A61K 31/381, A61K 31/4172, A61K 31/325

424427000, 514478000, 514317000, 514319000, 514370000, 514313000, 514400000, 514405000, 514448000

Compositions capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

2004006, Apr 8, 2004

Sep 27, 2002

10/260448

Bruce Pfeffer - Fairport NY, US
Rosemarie Flick - Copiaque NY, US
Naveed Shams - Duluth GA, US
Stephen Bartels - Pittsford NY, US

A61K031/155, C07C281/18

514/632000, 564/228000

Small organic molecules capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

2011007, Mar 31, 2011

Mar 26, 2010

12/732460

Bruce A. Pfeffer - Fairport NY, US
Charu A. DeWitt - Pittsford NY, US
Keith W. Ward - Ontario NY, US
Francisco J. Lopez - Victor NY, US

A61K 31/4709, A61P 29/00, A61P 27/02, A61P 3/10

514313

A composition for treating or controlling an ocular disease or condition comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), which disease or condition has an etiology, or results, in inflammation. The composition can optionally include an anti-inflammatory agent, an anti-infective agent, or both. The composition can be formulated for topical application, injection, or implantation in an affected eye to treat or control the ocular inflammatory disease or condition.